Progyny (PGNY): A Pure-Play on One of Society's Biggest Problems
Fertility benefits, demographic collapse, and a misunderstood compounder trading at half its 2024 highs
Every once in a while, the market hands you a business that does something genuinely important – and prices it as if nobody cares. Progyny is, in my view, one of those situations right now. The stock changed hands around 19 USD over the last days, the market cap is somewhere around 1.5 billion USD, and the company is sitting on roughly 310 million in cash with zero debt. A few months ago, on the back of weak initial 2026 guidance, the stock got cut by more than 20 percent in a single session. That is the kind of move that gets my attention, especially when the underlying business is profitable, generating record cash flow, and addressing what may turn out to be the single biggest structural problem of the developed world.
Elon Musk has been hammering one point on Twitter/X for years now: that population collapse from low birth rates is, in his view, a bigger long-term threat to civilization than climate change. You can argue about whether that framing is right – demographers at the UN clearly disagree, and global population is still growing thanks to Africa and South Asia. But the part that is hard to dispute is this: in the developed world, fertility rates have collapsed below replacement, the baby boomers are retiring, our pension systems were not designed for this, and politicians barely talk about it. Women are entering careers later, having children later, and from around age 35 onward the biological probability of natural conception drops sharply while miscarriage risk rises. That gap – between when people want to start a family and when their biology cooperates – is exactly where Progyny sits.
This is one of those healthcare investments where the thesis is straightforward enough that a non-doctor can hold it: fertility treatment demand is structurally rising, employers are increasingly paying for it as a benefit, and Progyny is more or less the only listed pure-play in the United States. The company has compounded revenue every year since IPO, generated 210 million USD in operating cash flow in 2025, and just raised full-year 2026 guidance on its Q1 print last week. Yet the stock trades at roughly its 2019 IPO price, and on my numbers offers something like 15 percent annualized upside over the next three years toward fair value, plus optionality from policy tailwinds I will get into later.
Full disclosure up front: Progyny is a position in the Haas Invest4 Innovation Fund. None of what follows is investment advice. With that out of the way – here is why I think this name belongs on your watchlist.
“Population collapse due to low birth rates is a much bigger risk to civilization than global warming.” — Elon Musk on Twitter/X. Whether you agree or not, the demographic data in the OECD is unambiguous.
1. Product, Business Model, Brand and Moat
What does Progyny actually do?
Progyny is a benefits-management company headquartered in New York. The product they sell is a fertility and family-building benefit that large U.S. employers offer to their workforce alongside health insurance, dental and vision. Think of it as a specialized carve-out: an employee at Google, Microsoft, Unilever or one of Progyny’s 600-plus client companies can access a curated network of top-tier fertility clinics, an integrated specialty pharmacy for hormone medications, and – critically – a dedicated human Patient Care Advocate who walks them through what is, for most people, one of the most emotionally difficult medical journeys of their life.
I have friends and family who have been through IVF. The clinical part is hard. The emotional and logistical part is harder. You are dealing with conflicting opinions from doctors, an overwhelming amount of jargon, hormone injections that have to be timed precisely, and a process that often fails on the first attempt. Having one specialized advocate on speed-dial – rather than just whichever doctor happens to be available – is genuinely valuable. Progyny’s clinical data backs this up: the company reports a roughly 61 percent pregnancy rate versus a national average around 53 percent, with lower miscarriage rates and fewer multiple births. That sounds incremental until you remember that each IVF cycle in the U.S. costs 15,000 to 20,000 USD. Better first-cycle success means fewer cycles, which means lower cost for the employer and less time the employee is away from work physically and emotionally.
Business model: B2B2C with the employer paying
The revenue model is elegant. Progyny does not sell to individuals. It signs contracts with large self-insured employers who pay Progyny on a per-employee-per-month (PEPM) basis to make the benefit available, plus utilization-based fees when employees actually use it. Revenue is split roughly two-thirds fertility benefit services and one-third pharmacy benefit services through the integrated specialty pharmacy. Margins on the pharmacy side are thinner but the business is sticky, because the medications are integrated into the same care pathway.
In 2025, the company generated 1.29 billion USD in revenue, up 10 percent year-over-year on a reported basis. The reported number understates the underlying trajectory: one very large client – widely reported to have been a major tech employer (Amazon) – ended its relationship with a transition agreement in 2024-25, which dragged down headline growth. Excluding that one client, 2025 revenue grew 20 percent. That is the number that matters. Gross margin expanded from 21.7 percent to 23.6 percent, adjusted EBITDA reached 222 million USD (a 17.2 percent margin), and net income came in at 58.5 million USD. The company has been GAAP-profitable every year since 2018 – something almost no other healthcare-tech name with this growth profile can claim.
Brand and moat
Progyny’s brand inside HR departments is the moat. When you are a Chief People Officer at a Fortune 500 company and a board member asks ‘are we doing enough on family-building benefits,’ Progyny is the name on the shortlist. The company won early by signing the tech bellwethers – Google, Meta and similar names – at a moment when freezing eggs and covering IVF became a competitive recruiting tool in Silicon Valley. From there, it spread into financial services, professional services, consumer goods, and now automotive. By the end of 2024 roughly 47 percent of large U.S. employers were offering some form of fertility benefit, and Progyny’s selling-season retention sits near 100 percent. Clients essentially never leave once they are on the platform – the medical outcomes data and the employee satisfaction scores make it almost impossible for an HR team to justify switching.
Could a competitor replicate this? In theory, yes. Companies like Maven Clinic, Carrot Fertility and Kindbody compete in adjacent spaces. But none of them has the scale of clinical-outcomes data, the integrated pharmacy, or the public-market access that Progyny has. Building the curated provider network alone took years. The Smart Cycle benefit design – which lets employees use their allocation flexibly across IVF, egg freezing, donor services and so on – is genuinely well-engineered and well-protected by clinical evidence. I would call this a ‘narrow but durable’ moat. Not Visa-level, but solid enough that I am comfortable underwriting the next five years of competitive position.
2. The Market: Big, Growing, and Increasingly Politically Tailwind
Global ART (assisted reproductive technology) is one of the most reliable structural growth markets I have studied. The underlying drivers are not cyclical: women entering the workforce, later first-pregnancy ages, declining male fertility (a topic Progyny itself has been researching publicly), same-sex couples and single parents by choice, and rising employer willingness to pay. Market growth estimates cluster around 8-10 percent per year globally, which is unusually strong for a defensive healthcare sub-segment.
The U.S. specifically is where Progyny plays today, and the U.S. is where the political tailwind has gotten interesting. In February 2025, President Trump signed an executive order directing his administration to develop policy recommendations to expand IVF access and reduce out-of-pocket costs. In October 2025, the administration unveiled an agreement with EMD Serono to provide certain IVF medications (Gonal-f, Ovidrel, Cetrotide) at up to 84 percent off list price through a new direct purchasing platform, TrumpRx.gov, which launched in February 2026. And just this past Sunday, May 10, 2026, the Departments of Labor, Health and Human Services, and Treasury jointly proposed a rule creating a new category of ‘limited excepted benefits’ for fertility care – essentially letting employers offer standalone fertility insurance, similar to how they offer dental or vision today, with a lifetime cap of 120,000 USD per participant indexed to inflation.
This last development is, in my view, materially under-appreciated by the market. The proposed rule does not force employers to offer the benefit – but it dramatically lowers the regulatory friction of doing so, and it explicitly creates a legal pathway that benefits providers like Progyny can plug into. The American Society for Reproductive Medicine, Resolve and other industry bodies have been pushing for exactly this kind of framework for years. The fact that it is coming from a Republican administration, traditionally seen as ambivalent on reproductive issues, is a quiet sign that fertility has become a bipartisan pro-family issue rather than a culture-war flashpoint. JD Vance has talked publicly about wanting more babies. Trump himself has called himself ‘the father of IVF.’ The political risk on this name, from where I sit, is asymmetric to the upside.
On cyclicality: I would actually argue Progyny is mildly counter-cyclical. When the labor market is tight, employers compete with benefits, which helps Progyny add clients. When the labor market loosens, employees have more time and headspace to pursue family-building, which lifts utilization at existing clients. There is no version of the economic cycle where people stop wanting to have children. That is part of what makes this such an attractive defensive growth name.
3. Culture and Management
CEO Pete Anevski has been with Progyny since the early days and took over as CEO in 2020. CFO Mark Livingston joined more recently but has slotted in cleanly. The tone of the earnings calls – I have listened to several of them, most recently the Q1 2026 call on May 7 – is what I would call ‘boring in the best way.’ Anevski talks about member engagement, utilization rates, selling-season pipeline, and gross margin expansion. He does not talk about TAM in trillions, AI, or vague platform stories. The team is operational and disciplined, and the financial results show it.
A few specific signals that I take as positive: the board authorized a 200 million USD buyback program in November 2025, and management has already completed it – repurchasing 8.8 million shares (roughly 10 percent of the float at the time) at prices that, in hindsight, look like genuine value. On the Q1 call Anevski mentioned the board is evaluating a new authorization. That is how I want a management team to behave when their own stock is being mispriced: act decisively rather than hoard cash. Insider selling exists but appears largely tied to 10b5-1 plans rather than directional bets.
The recent launch of Progyny Select in April 2026 is the most interesting strategic move in a while. This is the company’s first fully-insured supplemental fertility and women’s health plan, designed specifically for small employers (the 50 million-plus Americans who work at companies too small to self-insure). It packages everything Progyny does today – the managed provider network, the Smart Cycle design, the Care Advocates – into a fixed PEPM pooled-risk product, distributed via brokers, health plans and general agents for 2027 plan year implementations. It also extends coverage across the full continuum of women’s health: adoption, surrogacy, pregnancy, postpartum, parenting and menopause. Strategically this is exactly the right move at exactly the right time, because the Trump ‘limited excepted benefits’ rule, if finalized as proposed, is the regulatory bridge that makes Progyny Select scalable. Management is positioning the company for the next leg before the catalyst fully plays out.
4. Financials: A Profitable Compounder With Hidden Growth
Let me put the numbers in a table so the picture is clear. These are reported full-year figures plus the midpoint of management’s 2026 guidance issued in February and reaffirmed/raised on the Q1 call last week.
The story the table tells is the story I keep coming back to. Headline revenue growth of 7 percent for 2026 looks unimpressive, until you remember that 2026 is the first clean year without the lost client weighing on the comparison. Underlying client growth and member engagement is running comfortably in the low double digits. Net income is set to nearly double in 2026 versus 2025 (101 million USD at the midpoint of guidance versus 58.5 million reported), driven by gross margin expansion, completed share repurchases, and a normalization of equity-comp tax effects.
Return on equity is in the high single digits today but is mechanically rising as the buyback shrinks the equity base. Adjusted EBITDA margins are running in the 17 percent range and management has guided for further gross margin expansion as the operations scale. There is no debt – the company has 310 million USD in cash and marketable securities, an undrawn 200 million USD revolver, and is essentially self-funding all growth from internal cash flow. For a company with this kind of growth profile, that balance sheet is unusual.
5. Valuation: My Fair PE Model Suggests Roughly 15% Annualized Upside
This is where I apply my Fair PE / QFMA framework. The idea is simple: instead of debating multiples in isolation, I model what a reasonable, mid-cycle earnings number looks like three to five years out, apply a fair multiple based on growth, quality and risk, and back into an implied return. Let me walk through it.
On a TTM basis, Progyny trades at roughly 27-28x reported earnings and about 17x my estimate of 2026 adjusted EPS at the midpoint of guidance. Price-to-sales has compressed from over 6x at the 2021 peak to roughly 1.1x today. That is a remarkable derating for a business that has continued to compound revenue and cash flow throughout. EV/EBITDA on 2026E sits around 5-6x once you back out the net cash.
For my fair-value work, I assume Progyny continues to grow underlying revenue at low-to-mid teens through 2028, that gross margins expand modestly toward 25 percent, that the recent buyback authorization is renewed and another roughly 5-10 percent of shares are retired, and that Progyny Select plus the Trump excepted-benefits rule provide a modest tailwind in 2027-28. Under those assumptions, I get to approximately 2.00 USD in diluted EPS for fiscal 2028.
My fair PE for a business of this quality – defensive growth, durable client base, mid-teens revenue compounding, profitable, net cash, mid-to-large mid-cap – is 23x. Applying that to my 2028 EPS estimate of 2.00 USD gives a fair value of roughly 46 USD per share in 2028. Against today’s price near 19 USD, that implies a roughly 15 percent annualized return over the next three years, before considering any further buybacks or dividend initiation. If the Trump rule materially accelerates small-employer adoption via Progyny Select, the multiple could expand further; if the macro environment deteriorates or a major client churns, the multiple could compress. But the central case, on what I view as fairly conservative assumptions, gives me a clear path to mid-teens annualized returns.
Fair PE = 23. EPS 2028E = 2.00 USD. Fair value 2028 ≈ 46 USD. Annualized upside from ~19 USD: ~15% per year over three years, before any further buybacks.
6. Risks: How Did We Get From 60 USD to 19 USD?
Honest valuation work means asking why the stock is here in the first place. Progyny peaked above 60 USD in late 2021 during the post-COVID growth-stock blow-off. From there, the derating has been a textbook compression of a high-multiple name during a rising-rate environment. But that alone does not explain why the stock has continued to leak lower in 2026 specifically. Let me lay out the actual concerns.
Loss of a major client. A very large client – disclosed publicly only as a transition arrangement – did not renew for 2025, with extended transition revenue running through the first half. That client contributed roughly 136 million USD in 2024 revenue, dropping to 48.5 million in 2025 and almost nothing in 2026. Reported growth optics have been poor as a result, and the market has clearly punished the headline number.
Soft initial 2026 guidance. When Progyny reported Q4 2025 on February 26, 2026, the initial 2026 guidance came in below sell-side expectations and the stock dropped roughly 20 percent in a single session. The Q1 2026 print on May 7 walked some of that back – revenue came in above the high end of guidance, EPS beat consensus, and management raised full-year EBITDA, net income and EPS guidance – but sentiment is still bruised.
Member-engagement variability. Progyny’s revenue depends on members actually using the benefit in any given period. Management saw a soft patch in 2024 where utilization ran below historical norms. They have since said engagement has normalized, but the market remains nervous about whether it could happen again.
Concentration risk. The top 10 clients still represent a meaningful share of revenue. Losing another anchor client – particularly a major tech employer – would hit reported numbers hard, just as it did in 2025.
Competition. Maven Clinic raised at a roughly 1.7 billion USD private valuation. Carrot Fertility, Kindbody and others are well-funded. Progyny’s outcomes data is the moat, but private competitors can keep pricing aggressive.
Regulatory ambiguity. The proposed Trump ‘limited excepted benefits’ rule could, in a worst-case interpretation, allow some employers who currently cover IVF inside their general health plan to spin it out into a less generous standalone product. The net effect on Progyny is most likely positive – more employers, broader access – but the transition could be messy.
Governance noise. There was a recent settlement and governance reforms around director pay disclosed in March 2026. Not a thesis-killer, but worth noting.
My take: most of these risks are well-known and arguably already priced in. The lost client is now anniversaried. The soft initial guidance has been raised twice. Engagement has stabilized. The buyback shows the board agrees the stock is mispriced. The risk-reward asymmetry, in my view, is now favorable rather than balanced.
7. Latest Earnings and Recent News
The Q1 2026 earnings call on May 7 was the most important recent data point. The headline numbers: revenue of 328.5 million USD (1.4 percent reported growth, more than 12 percent excluding the transition client), adjusted EPS of 0.50 USD versus 0.44 consensus, and a full-year guidance raise on EBITDA, net income and EPS. The stock jumped 17.5 percent intraday on the print – a meaningful rebound from the February drawdown.
Pete Anevski’s commentary on the call was the most upbeat he has sounded in a while. He highlighted that member engagement is consistent with what was assumed in February guidance, that gross margin expansion is being driven by ‘lasting operational efficiencies’ rather than one-off items, and that the 2027 selling season is ‘ahead of prior years in both pipeline and client retention activity.’ He also flagged early progress with Progyny Select among health plan partners and distribution channels – exactly the language an analyst wants to hear about a brand-new product line.
Beyond earnings, the news flow in the last sixty days has been almost uniformly constructive:
April 16, 2026: Launch of Progyny Select, the industry’s first fully-insured supplemental fertility plan for small employers, distributed through brokers, health plans and general agents for 2027 plan-year implementations.
May 7, 2026: Q1 2026 earnings beat across revenue, EPS and EBITDA; full-year guidance raised.
May 10, 2026: Trump administration’s Departments of Labor, HHS and Treasury jointly propose a new ‘limited excepted benefits’ rule for fertility care, with a 120,000 USD lifetime cap, indexed to inflation.
May 12, 2026: CEO Pete Anevski and CFO Mark Livingston present at the BofA Securities 2026 Healthcare Conference fireside chat.
Completed 200 million USD buyback authorization; board evaluating a new authorization.
On Twitter/X, the conversation around the stock has shifted from frustration about the February guide-down to renewed interest after the Q1 beat. The combination of strong fundamentals, a tangible regulatory tailwind, and a stock price that screens cheap on almost any framework is starting to attract value-oriented investors who missed the 2020-21 growth-investor wave.
8. Conclusion and Investment Case
Progyny is, in my view, a rare combination of attributes that I look for in a long-term position. Let me summarize what I think the catalysts are for a re-rating from here:
Demographic tailwind. OECD fertility rates continue to decline, average age at first birth continues to rise, and the structural demand for fertility services is one of the most reliable secular trends in healthcare.
Trump-administration policy support. From the February 2025 executive order to TrumpRx.gov pricing on IVF medications to the May 2026 proposed rule on limited excepted benefits, Washington is actively lowering the friction for fertility coverage. This is rare bipartisan-feeling tailwind for a healthcare name.
Progyny Select. Opens a 50-million-employee addressable market of small-employer workers that Progyny historically could not serve. First revenues will hit in 2027 plan-year launches.
Clean comparisons starting 2026. The transition-client headwind is now in the rear-view mirror. From 2026 onward, headline numbers will reflect underlying growth, which is in the low double digits.
Capital returns. Management completed a 200 million USD buyback and is evaluating another authorization. With 310 million USD in cash and 200 million in undrawn revolver, the optionality is substantial.
Valuation. Roughly 17x 2026E adjusted earnings, about 1.1x sales, and 5-6x EV/EBITDA for a profitable, net-cash, mid-teens-growth business solving a societal-level problem. The market is paying a defensive-utility multiple for a defensive growth compounder.
My fair-PE framework points to roughly 46 USD per share fair value by 2028, or about 15 percent annualized upside from here. That is not a moonshot. It is a sober, plausible return for a high-quality business that the market temporarily dislikes. The downside scenarios I can construct – another major client loss, a sharp recession, a competitive price war – are real but appear largely priced in at current levels.
This is the kind of position I want to own a meaningful amount of and just leave alone. No constant trading, no chasing quarterly noise – just compound at low-double-digit revenue growth, mid-teens EPS growth, and let the multiple do whatever it does. The world is going to keep needing what Progyny sells. Demographics do not reverse on quarterly earnings cycles.
If you believe that birth rates in developed economies will continue to fall, that women will continue to enter careers and have children later, that employer benefits will continue to expand, and that government policy will keep tilting toward access – then Progyny is one of the cleanest ways to express that thesis in public equity markets today.